论文部分内容阅读
采用化疗的同时服用扶正口服液为治疗组；化疗相同不服用扶正口服液为对照组。结果：该制剂改善患者生存质量率为57.5%，对照组为28%。经统计学处 理表明治疗组与对照组比较生存质量有显著性差异(P＜0.05)。该制剂可直接改善癌症患者 在接受化疗期间的生存质量。
Taking Fuzheng Oral Liquid as the treatment group while using chemotherapy, and taking Fuzheng Oral Liquid as the control group. RESULTS: The formulation improved the patient’s quality of life rate by 57.5% and the control group by 28%. Statistical analysis showed that there was a significant difference in quality of life between the treatment group and the control group (P<0.05). The formulation can directly improve the quality of life of cancer patients during chemotherapy.